About PGxl

PGXL is an internationally recognized pioneer in the application of molecular diagnostics to pharmacogenetics and is the first laboratory to be CLIA-certified specifically for pharmacogenetics testing. The company was founded in 2005 by Dr. Roland Valdes, Jr., and Dr. Mark W. Linder, researchers who are among the worldwide thought leaders in the science underlying personalized medicine. Our scientists are leading the way in the incorporation of genetic information into the practice of medicine.

News

• PGXL in Joint Venture to Commercialize Sleep Apnea Diagnostic

  PGXL/Laboratories and its sister company, PGXL/Technologies, have entered into a joint venture with Appian Partners LLC of Severna Park, Maryland, ...

• Equity Investment in PGXL

  The University of Louisville Foundation has made a "substantial" equity investment in PGXL, helping to fund the expansion of the ...

• Contract Research Portfolio Grows

  PGXL will provide laboratory services for SK Life Science, which manages global clinical trials of new drugs. The contract will ...

• PGXL Receives Capital Equipment Support From State of Kentucky

  PGXL has received a $200,000 forgivable loan from the Kentucky Economic Development Finance Authority to purchase capital equipment. Governor Steve ...